Townhall Review – September 15, 2018
Hugh Hewitt and Congressman Mike Gallagher take a look at the crisis in Syria, with Assad threatening to use chemical weapons. Michael Medved questions the importance of the anonymous New York Times op-ed that Democrats are salivating over. Mark Davis comments on former President Obama breaking past-president protocol, publicly criticizing the current President and the Republican Party. Google’s CEO snubs the U.S. Senate, ignoring a request to talk about media censorship. Dennis Prager and Louisiana Senator Bill Cassidy discuss the media bias against Prager University. Michael Medved’s guest, John Bozzella, President and CEO of Global Automakers, says recent tariffs imposed by President Trump are causing auto prices to soar. Hugh Hewitt talks with Ken Starr, who’s Special Counsel work lead to President Clinton’s impeachment, about the likelihood of Trump’s impeachment. Dennis Prager and his producer Allen Estrin discuss President Trump’s phone call with Jewish leaders in media and politics.Read More »
There’s been a lot of talk recently about whether NATO—an alliance started after World War II—is still relevant in today’s world. The answer is a simple and unequivocal “yes.” It is.
The alliance is on the front lines of our efforts to counteract Russia’s growing ambitions in Europe and beyond. But NATO does need to evolve, to meet the growing threats of the 21st century. It should be oriented, for example, toward efforts to counter the growing threats of cyber-terrorism and Russian efforts to meddle in democratic elections in member nations.
And: NATO members must contribute their fair share. President Trump is right to press our European allies to invest more in their own defensive capacities.
But NATO has been, and continues to be, an integral part of our national security strategy.
It’s an alliance worth defending.Read More »
President Trump recently announced his plan to lower prescription drug costs. It’s a solid plan that strikes the delicate balance between promoting innovation with the need to ensure that consumers have access to the medicines they need at a price they can afford.
Meanwhile, liberal politicians are continuing their calls for government price controls on prescription drugs, all while trumpeting the virtues of single-payer health care. Both policies would lead to lower quality care, more limited access to needed cures, and result in much higher government spending.
What our health care system needs is more competition to drive down prices. This plan helps.
The Trump Administration is right to focus on policies that speed access to the marketplace for generic drugs and new cures. Lower prices won’t happen overnight, but the policies the president has proposed will make a difference.Read More »